SCHEMBL6001206

SCHEMBL6001206

Fc1ccc(-c2cc3ccccc3c(Nc3ccc4c(c3)OCO4)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.54
MEN1 O00255 8/20 0.54
HSD17B10 Q99714 6/20 0.54
ALDH1A1 P00352 5/20 0.54
ALOX15 P16050 4/20 0.54
MAPK1 P28482 4/20 0.54
CYP1A2 P05177 3/20 0.54
CYP3A4 P08684 3/20 0.54
CYP2D6 P10635 3/20 0.54
CYP2C19 P33261 3/20 0.54
LMNA P02545 3/20 0.54
CLK4 Q9HAZ1 3/20 0.54
TP53 P04637 2/20 0.54
USP2 O75604 2/20 0.54
TSHR P16473 2/20 0.54
MAPT P10636 6/20 0.53
HTT P42858 2/20 0.53
NOD2 Q9HC29 1/20 0.53
TGFBR1 P36897 1/20 0.53
NPC1 O15118 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001965 0.82 ACP1 (0.61) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL6001170 0.81 LMNA (0.77) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL29007307 0.80 ABCG2 (0.60) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL30390170 0.80 ABCG2 (0.60) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL6001182 0.80 HSD17B10 (0.49) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL6001831 0.77 KDR (0.45) KMT2AMEN1LMNAMAPTHPGD
SCHEMBL6001386 0.76 TP53 (0.58) KMT2AMEN1HSD17B10ALDH1A1ALOX15
SCHEMBL6001681 0.75 ABCG2 (0.62) KMT2AMEN1LMNATP53MAPT
SCHEMBL6001423 0.74 ABCG2 (0.64) KMT2AMEN1LMNATP53MAPT
SCHEMBL4531381 0.73 MKNK2 (0.53) KMT2AMEN1HSD17B10ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060128702-A1 Heterocyclic and bicyclic compounds, compositions and methods REDDY US THERAPEUTICS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128702-A1 Heterocyclic and bicyclic compounds, compositions and methods HPSE, ENGASE, UGCG KMT2A 3343/4885MEN1 2168/4885HSD17B10 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.